People in the US have received more than 342 million doses of COVID-19 vaccines, with the vast majority being mRNA vaccines from Pfizer-BioNTech or Moderna. In the study by Klein et al, the mRNA COVID-19 vaccines were safe for the population overall (ie, there was no difference for an...
2. Structure and pathogenicity of SARS-CoV-2 3. LNPs-mRNA complex immunogenicity 4. Efficacy and safety of mRNA vaccines 5. Covid vaccination psychological impact 6. Conclusions Funding CRediT authorship contribution statement Declaration of Competing Interest Acknowledgements ReferencesShow full outline ...
13,20 Furthermore, concerns for the safety of mRNA vaccines have been raised.21,22 Therefore, pooled evidence regarding the efficacy and safety of mRNA vaccines among children aged 5 to 11 years will inform physicians, families, and policy makers. We conducted a systematic review and meta-...
Multivariable logistic regression was used to examine the association between BNT162b2/mRNA-1273 COVID-19 vaccines and two short-term health events: 1) health event preventing daily activities and/or required medical consultation, 2) serious health events resulting in an emergency department visit ...
BACKGROUND: Vaccines based on mRNA coding for antigens have been shown to be safe and immunogenic in preclinical models. We aimed to report results of the first-in-human proof-of-concept clinical trial in healthy adults of a prophylactic mRNA-based vaccine encoding rabies virus glycoprotein (CV...
M. et al. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann. Rheum. Dis. https://ard.bmj.com/content/early/2021/05/11/annrheumdis-2021-220272 (2021). Simon, D. et al. ...
In all reported RABV mRNA vaccination studies, outstanding protective immune responses were induced in mice and dogs. However, a more clinically relevant animal model, such as non-human primates, has not been used to evaluate the safety and immunogenicity of mRNA vaccines. We previously reported ...
mRNA biodistribution for Nucleic Acid–Based Vaccines mRNA vaccines represent a promising alternative to conventional vaccine approaches because of their high potency, capacity for rapid development, and potential for low-cost manufacturing and safe administration. However, their application has been re...
Despite the very low risk-to-benefit ratio of vaccines, fear of negative side effects has discouraged many people from getting vaccinated, resulting in reemergence of previously controlled diseases such as measles, pertussis, and diphtheria. Part of this fear stems from the lack of public awareness...
Self-replicating RNA (srRNA) technology, in comparison to mRNA vaccines, has shown dose-sparing by approximately 10-fold and more durable immune responses. However, no improvements are observed in the adverse events profile. Here, we develop an srRNA vac